» Articles » PMID: 25580670

What the Eczema Area and Severity Index Score Tells Us About the Severity of Atopic Dermatitis: an Interpretability Study

Overview
Journal Br J Dermatol
Specialty Dermatology
Date 2015 Jan 13
PMID 25580670
Citations 103
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The Eczema Area and Severity Index (EASI) is an investigator-assessed instrument measuring the severity of clinical signs in atopic dermatitis (AD). The EASI was identified as one of the best-validated outcome measures for AD; however, no previous studies address how to interpret the EASI score for clinical use.

Objectives: To evaluate the interpretability and the ease of use of the EASI.

Methods: A retrospective analysis of paediatric and adult patients with AD was performed. Interpretability was evaluated by stratifying the EASI scores according to the Investigator's Global Assessment. The severity strata displaying the highest kappa coefficient of agreement were then selected as the recommended EASI band. The time to administer the EASI was recorded in a subgroup of patients.

Results: The suggested severity strata for the EASI are as follows: 0 = clear; 0·1-1·0 = almost clear; 1·1-7·0 = mild; 7·1-21·0 = moderate; 21·1-50·0 = severe; 50·1-72·0 = very severe (κ = 0·75). The EASI was also found to be acceptable in terms of ease of use, with assessments by trained investigators taking approximately 6 min.

Conclusions: Our study provides the first guide for interpreting the EASI score. It enables translation of the EASI numerical output into an AD global severity state that should be more meaningful to providers and patients. Along with a short administration time, the EASI demonstrates adequate feasibility, further supporting its use in clinical trials.

Citing Articles

Burden of mild and moderate atopic dermatitis in adults: results from a real-world study in the United States.

Silverberg J, Anderson P, Cappelleri J, Piercy J, Levenberg M, Myers D Arch Dermatol Res. 2025; 317(1):556.

PMID: 40072609 PMC: 11903610. DOI: 10.1007/s00403-025-03910-y.


Roads to remission: evolving treatment concepts in type 2 inflammatory diseases.

Lommatzsch M, Blumchen K, Beck L, Bousquet J, Brusselle G, Fokkens W EClinicalMedicine. 2025; 80:103050.

PMID: 39867971 PMC: 11764424. DOI: 10.1016/j.eclinm.2024.103050.


Risk Factors Associated with Weight Gain during Treatment with Dupilumab among Patients with Moderate to Severe Atopic Dermatitis.

Tayefi M, Svedbom A, Ivert L, Lundqvist M, Ruas J, Bradley M Acta Derm Venereol. 2024; 104:adv40796.

PMID: 39545373 PMC: 11586677. DOI: 10.2340/actadv.v104.40796.


Cost-Effectiveness Study of Difamilast 1% for the Treatment of Atopic Dermatitis in Adult Japanese Patients.

Nakahara T, Noto S, Matsukawa M, Takeda H, Zhang Y, Kondo T Dermatol Ther (Heidelb). 2024; 14(11):3113-3132.

PMID: 39487325 PMC: 11557786. DOI: 10.1007/s13555-024-01300-2.


Unmet Medical Needs and Early Referral of Pediatric Atopic Dermatitis: An Expert Modified Delphi Consensus from Saudi Arabia.

Alradaddi A, Al Twaim A, Abu-Aliat A, Al-Atass K, Alogayell L, Aldayil M Dermatol Res Pract. 2024; 2022:5636903.

PMID: 39444785 PMC: 11496595. DOI: 10.1155/2022/5636903.